A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : AC / adriamycin and cyclophosphamide

[Related PubMed/MEDLINE]
Total Number of Papers: 92
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   AC  (>> Co-occurring Abbreviation)
Long Form:   adriamycin and cyclophosphamide
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2019 Fixed combination of oral NEPA (netupitant-palonosetron) for the prevention of acute and delayed chemotherapy-induced nausea and vomiting in patients receiving multiple cycles of chemotherapy: Efficacy data from 2 randomized, double-blind phase III studies. CINV, CR, NEPA
2019 Metaplastic breast cancer has a poor response to neoadjuvant systemic therapy. ER, MetaBC, NAC, pCR, PR
2019 One-Day Versus Three-Day Dexamethasone in Combination with Palonosetron for the Prevention of Chemotherapy-Induced Nausea and Vomiting: A Systematic Review and Individual Patient Data-Based Meta-Analysis. CI, CINV, CR, d3 arm, IPD, MEC
2019 Outcomes of early-stage breast cancer patients treated with sequential anthracyclines-taxanes in relationship to relative dosing intensity: a secondary analysis of a randomized controlled trial. RDI
2019 Phase IIIb Safety and Efficacy of Intravenous NEPA for Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Patients with Breast Cancer Receiving Initial and Repeat Cycles of Anthracycline and Cyclophosphamide (AC) Chemotherapy. AE, CINV, NK-1, RA
2019 Survival outcome of combined GnRH agonist and tamoxifen is comparable to that of sequential adriamycin and cyclophosphamide chemotherapy plus tamoxifen in premenopausal patients with early breast cancer. AC-TAM, GnRH
2018 Chronic Treatment with Combined Chemotherapeutic Agents Affects Hippocampal Micromorphometry and Function in Mice, Independently of Neuroinflammation. ---
2018 Comparative efficacy and tolerability of antiemetic prophylaxis for adult highly emetogenic chemotherapy: A network meta-analysis of 143 randomized controlled trials. CDO, CINV, DO
2018 Control of Nausea and Vomiting in Patients Receiving Anthracycline/Cyclophosphamide Chemotherapy for Breast Cancer. CINV
10  2018 Effects of anthracycline, cyclophosphamide and taxane chemotherapy on QTc measurements in patients with breast cancer. BNP, QTdc
11  2018 Efficacy and Safety of Oral NEPA (Netupitant/Palonosetron), the First Fixed-Combination Antiemetic, in Patients With Gynecological Cancers Receiving Platinum-Based Chemotherapy. CINV, CR, CT
12  2018 Efficacy of assessing circulating cell-free DNA using a simple fluorescence assay in patients with triple-negative breast cancer receiving neoadjuvant chemotherapy: a prospective observational study. baseline-CFD, CFD, pCR, TNBC
13  2018 Evaluation of factors contributing to the response to fosaprepitant in a heterogeneous, moderately emetogenic chemotherapy population: an exploratory analysis of a randomized phase III trial. CINV, CR, MEC
14  2018 Four cycles of adriamycin and cyclophosphamide followed by four cycles of docetaxel (NSABP-B27) with concomitant trastuzumab as neoadjuvant therapy for high-risk, early-stage, HER2-positive breast cancer patients. DFS, HER2, NSABP-B27
15  2018 Incidence of nausea and vomiting in breast cancer patients treated with anthracycline plus cyclophosphamide-based chemotherapy regimens in Italy: NAVY observational study. CINV
16  2018 Neuropilin-1 promotes the oncogenic Tenascin-C/integrin beta3 pathway and modulates chemoresistance in breast cancer cells. FAK, ITGB3, NF-kB, NRP-1, TN-C
17  2018 Phase III safety study of intravenous NEPA: a novel fixed antiemetic combination of fosnetupitant and palonosetron in patients receiving highly emetogenic chemotherapy. AEs, CINV, DEX, HEC, i.v
18  2018 Rolapitant for the prevention of nausea in patients receiving highly or moderately emetogenic chemotherapy. AB, NK1RAs
19  2018 The cost-effectiveness of neoadjuvant chemotherapy in women with locally advanced breast cancer: Adriamycin and cyclophosphamide in comparison with paclitaxel and gemcitabine. PG
20  2018 The effect of adjuvant chemotherapy on survival in Korean patients with node negative T1c, triple negative breast cancer. CMF, OS, TNBC
21  2017 2016 Updated MASCC/ESMO consensus recommendations: Emetic risk classification and evaluation of the emetogenicity of antineoplastic agents. ---
22  2017 2016 Updated MASCC/ESMO Consensus Recommendations: Prevention of Nausea and Vomiting Following High Emetic Risk Chemotherapy. HEC
23  2017 Acute Inflammatory Response During Neoadjuvant Chemotherapy for Locally Advanced Breast Cancer: A Case Report. HER2, pCR
24  2017 APF530 versus ondansetron, each in a guideline-recommended three-drug regimen, for the prevention of chemotherapy-induced nausea and vomiting due to anthracycline plus cyclophosphamide-based highly emetogenic chemotherapy regimens: a post hoc subgroup analysis of the Phase III randomized MAGIC trial. CINV, CR, HEC, MAGIC
25  2017 Chemotherapy-induced irreversible alopecia in early breast cancer patients. AC-T, CIIA
26  2017 Comparison of an AC-taxane versus AC-free regimen and paclitaxel versus docetaxel in patients with lymph node-positive breast cancer: Final results of the National Surgical Adjuvant Study of Breast Cancer 02 trial, a randomized comparative phase 3 study. DFS, DTX, HR, PTX
27  2017 Efficacy and safety of aprepitant for the prevention of chemotherapy-induced nausea and vomiting during the first cycle of moderately emetogenic chemotherapy in Korean patients with a broad range of tumor types. CINV, CR, MEC
28  2017 Efficacy of ginger for prophylaxis of chemotherapy-induced nausea and vomiting in breast cancer patients receiving adriamycin-cyclophosphamide regimen: a randomized, double-blind, placebo-controlled, crossover study. CINV
29  2017 Efficacy of NEPA (netupitant/palonosetron) across multiple cycles of chemotherapy in breast cancer patients: A subanalysis from two phase III trials. 5-HT3RA, BC, CINV, CR, DEX, NK1RA
30  2017 MYC Amplification as a Predictive Factor of Complete Pathologic Response to Docetaxel-based Neoadjuvant Chemotherapy for Breast Cancer. ---
31  2017 Prevention of chemotherapy-induced nausea: the role of neurokinin-1 (NK1) receptor antagonists. CIN, HEC, MEC, NK-1, RAs
32  2017 Rolapitant improves quality of life of patients receiving highly or moderately emetogenic chemotherapy. CINV, FLIE, HEC, MEC
33  2017 Safety and efficacy of NEPA, an oral fixed combination of netupitant and palonosetron, in older patients. CR, HEC, non-AC MEC, RA
34  2016 A case of slowly progressive anti-Yo-associated paraneoplastic cerebellar degeneration successfully treated with antitumor and immunotherapy. IVIG, mRS, PCD
35  2016 Defining the efficacy of neurokinin-1 receptor antagonists in controlling chemotherapy-induced nausea and vomiting in different emetogenic settings-a meta-analysis. AD, CINV, CR, HEC, MDC, NK1RAs, OR
36  2016 Serial MRI scans help in assessing early response to neoadjuvant chemotherapy and tailoring breast cancer treatment. NAC, PR
37  2016 Should clinicians always administer dexamethasone beyond 24 h after chemotherapy to control delayed nausea and vomiting caused by moderately emetogenic regimens? Insight from the re-evaluation of two randomized studies. CP, MEC
38  2015 Effect of increase in duration of aprepitant consumption from 3 to 6 days on the prevention of nausea and vomiting in women receiving combination of anthracycline/cyclophosphamide chemotherapy: A randomized, crossover, clinical trial. ---
39  2015 Efficacy of dose dense doxorubicin and cyclophosphamide followed by paclitaxel versus conventional dose doxorubicin, cyclophosphamide followed by paclitaxel or docetaxel in patients with node-positive breast cancer. BC, DD, DFS, OS
40  2015 Evaluation of the Survival Benefit of Different Chemotherapy Regimens in Patients with T1-2N0 Triple-Negative Breast Cancer. CMF, FAC
41  2015 Netupitant/Palonosetron: A Review in the Prevention of Chemotherapy-Induced Nausea and Vomiting. CINV, HEC, MEC, NEPA
42  2015 Open-label, randomized, comparative, phase III study on effects of reducing steroid use in combination with Palonosetron. CI, CINV, CR, DEX, MEC, PALO
43  2015 Palonosetron in the prevention of chemotherapy-induced nausea and vomiting: an evidence-based review of safety, efficacy, and place in therapy. CINV, NK-1
44  2015 Pneumocystis jiroveci pneumonia (PCP) in patients receiving neoadjuvant and adjuvant anthracycline-based chemotherapy for breast cancer: incidence and risk factors. DFCI/BWH, PCP
45  2015 Resource Utilization for Chemotherapy-Induced Nausea and Vomiting Events in Patients with Solid Tumors Treated with Antiemetic Regimens. CINV, HEC, MEC, NK-1
46  2014 Efficacy of a triple antiemetic regimen with aprepitant for the prevention of chemotherapy-induced nausea and vomiting: effects of gender, age, and region. CINV
47  2014 Toxicity and quality of life of Korean breast cancer patients treated with docetaxel-containing chemotherapy without primary G-CSF prophylaxis. G-CSF, QOL
48  2013 Palonosetron plus single-dose dexamethasone for the prevention of nausea and vomiting in women receiving anthracycline/cyclophosphamide-containing chemotherapy: meta-analysis of individual patient data examining the effect of age on outcome in two phase III trials. CR
49  2013 Trastuzumab-related cardiac events in the treatment of early breast cancer. CE, HER2, LVEF
50  2013 [A case of chest wall recurrence after mastectomy for breast cancer that showed response to chemotherapy]. PET, US
51  2013 [A case of effective trastuzumab plus gemcitabine therapy for human epidermal growth factor receptor 2-positive breast cancer]. CEA, ER, PD, PgR
52  2012 Adjuvant chemotherapy with six cycles of AC regimen versus three cycles of AC regimen followed by three cycles of Paclitaxel in node-positive breast cancer. EBRT
53  2012 Changes in leukocyte gene expression profiles induced by antineoplastic chemotherapy. ATM, CT, MATR3, MORC3, PBLs, PC, ZNF644
54  2012 It is not only the empty vials that go into the garbage can during chemotherapy drugs preparation: a cost analysis of unused chemotherapy drugs in cancer treatment. ---
55  2012 Palonosetron plus 1-day dexamethasone for the prevention of nausea and vomiting due to moderately emetogenic chemotherapy: effect of established risk factors on treatment outcome in a phase III trial. CINV, MEC
56  2011 Differential time course of action of 5-HT3 and NK1 receptor antagonists when used with highly and moderately emetogenic chemotherapy (HEC and MEC). HEC, HEC and MEC, MEC
57  2011 Effect of phaleria macrocarpa supplementation on apoptosis and tumor growth of C3H mice with breast cancer under treatment with adriamycin-cyclophosphamide. PM
58  2011 NON-INVASIVE MEASUREMENT OF DEEP TISSUE TEMPERATURE CHANGES CAUSED BY APOPTOSIS DURING BREAST CANCER NEOADJUVANT CHEMOTHERAPY: A CASE STUDY. DOSI, NAC
59  2011 Palonosetron in combination with 1-day versus 3-day dexamethasone for prevention of nausea and vomiting following moderately emetogenic chemotherapy: a randomized, multicenter, phase III trial. CINV, CR, MEC
60  2011 Sleep aid prescribing practices during neoadjuvant or adjuvant chemotherapy for breast cancer. ---
61  2010 Aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with a broad range of moderately emetogenic chemotherapies and tumor types: a randomized, double-blind study. CINV, MEC
62  2009 Aprepitant as salvage antiemetic therapy in breast cancer patients receiving doxorubicin and cyclophosphamide. ---
63  2009 Patterns of sore mouth in outpatients with cancer receiving chemotherapy. SM, VGA
64  2009 Phase III trial of casopitant, a novel neurokinin-1 receptor antagonist, for the prevention of nausea and vomiting in patients receiving moderately emetogenic chemotherapy. MEC
65  2009 Short term results from GHRH analogue use in pre-menopausal breast cancer in Korea. ---
66  2008 Impact of a reduced dose intensity of adjuvant anthracycline based chemotherapy in a population-based cohort of stage I-II breast cancers. DI
67  2008 Impact of breast cancer chemotherapy on ovarian reserve: a prospective observational analysis by menstrual history and ovarian reserve markers. ACT
68  2008 Impact of neutropenia on delivering planned chemotherapy for solid tumours. DI, FEC, FN, G-CSF, RDI, SCLC
69  2007 A new model of patient tumor-derived breast cancer xenografts for preclinical assays. HBC, HER2
70  2007 Cytogenetic outcomes of adjuvant chemotherapy in non-target cells of breast cancer patients. PRI, SCEs
71  2007 MRI measurements of tumor size and pharmacokinetic parameters as early predictors of response in breast cancer patients undergoing neoadjuvant anthracycline chemotherapy. NR, ROC, SE
72  2006 The effect of the stromal component of breast tumours on prediction of clinical outcome using gene expression microarray analysis. SAM
73  2005 Neoadjuvant vinorelbine/epirubicin (VE) versus standard adriamycin/cyclophosphamide (AC) in operable breast cancer: analysis of response and tolerability in a randomised phase III trial (TOPIC 2). VE
74  2004 Modulation of thymidine phosphorylase by neoadjuvant chemotherapy in primary breast cancer. 5-FU, EC, FAC, FEC, TP
75  2003 [Taxanes in primary systemic treatment of breast cancer]. ---
76  2002 [Combined chemoendocrine therapy using adriamycin, cyclophosphamide and high dose toremifene in patients with recurrent breast cancer]. TOR
77  2001 A randomized trial of four cycles of adjuvant AC (adriamycin + cyclophosphamide) +/- two cycles of EP (etoposide + cisplatin) in node positive patients with breast cancer. DFS, EP, OS
78  2001 Adjuvant therapy of primary breast cancer: a review of key findings from the 7th international conference, St. Gallen, February 2001. 5-FU
79  2001 Future directions in the adjuvant treatment of breast cancer: the role of trastuzumab. EBCTCG, ER, NSABP
80  2001 Trastuzumab combined with chemotherapy for the treatment of HER2-positive metastatic breast cancer: pivotal trial data. ---
81  2001 Trials of new combinations of Herceptin in metastatic breast cancer. HER2
82  1999 Energy balance in women with breast cancer during adjuvant treatment. LBM
83  1999 Offering a choice between two adjuvant chemotherapy regimens: a pilot study to develop a decision aid for women with breast cancer. CMF
84  1998 Adjuvant systemic therapy for women with node-negative breast cancer. The Steering Committee on Clinical Practice Guidelines for the Care and Treatment of Breast Cancer. CMF, ER, LVI
85  1998 Continuous infusional chemotherapy for early breast cancer: the Royal Marsden Hospital experience. CR
86  1993 Recovery of response to adriamycin and cyclophosphamide by lonidamine in previously treated metastatic breast-cancer patients. ---
87  1987 Malignant ovarian tumors in children and adolescents. ADR, CHP, PBVb, RT, VB, VC
88  1984 Adriamycin and cyclophosphamide versus hydroxyurea in advanced prostatic cancer. A randomized Southwest Oncology Group study. SWOG
89  1982 Adjuvant treatment of node-positive breast cancer with adriamycin-cyclophosphamide with or without radiation therapy: interim results of an ongoing clinical trial. ---
90  1980 Salvage treatment of patients relapsing after breast cancer adjuvant chemotherapy. ---
91  1979 [Combination of adriamycin and cyclophosphamide (alone or with other substances) in the treatment of breast cancer]. ---
92  1979 [Current status in the treatment of breast cancer. II. Adjuvant chemotherapy, palliative polychemotherapy, chemoimmunotherapy--rating and results (author's transl)]. CMF, CMFVP